The sponsor reported 25.9% average weight reduction at 80 weeks in the TRIUMPH-1 9 mg arm under its efficacy analysis, versus 2.2% with placebo.
A Phase 3 target amount
The published study design makes the comparison with placebo interpretable within the trial. The difference between the 9 mg and 12 mg headline values is a separate question and needs its own uncertainty and statistical context.
How to interpret the evidence
Use the arm label as a research identifier and retain the analysis definition when summarizing the result.
This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.